NCT04971109View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

PHASE3CompletedINTERVENTIONAL
Enrollment

467

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

May 12, 2023

Study Completion Date

May 12, 2023

Conditions
Smallpox
Interventions
DRUG

TPOXX

Study is based on Animal Regulatory Rule

OTHER

TPOXX Placebo

Does not apply

Trial Locations (9)

27265

High Point Clinical Trials Center, High Point

29405

Coastal Carolina Research Center, North Charleston

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, LLC, Miami

33147

Advanced Pharma, Miami

45417

Midwest Clinical Research Center, Dayton

78744

PPD Phase I Clinic, Austin

68134-3664

Meridian Clinical Research, Omaha

08009

Hassman Research Institute, Berlin

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

SIGA Technologies

INDUSTRY